XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis

Journal of Experimental & Clinical Cancer Research

Li-Ke Yu²  Qian Qian²  Qin Wang¹  Ping Zhan² 

[1] Department of Respiratory Medicine, 81 Hospital of PLA, Nanjing, China;First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing, 210029, China

关键词: Meta-analysis;    Susceptibility;    Lung cancer;    Polymorphism;    XRCC3;   

Others  :  825528
DOI  :  10.1186/1756-9966-32-1

 received in 2012-12-05, accepted in 2013-01-03,  发布年份 2013

【 摘 要 】

Many studies have examined the association between the XRCC3 Thr241Met gene polymorphism and lung cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed, Embase, Web of Science, and CNKI database was searched for case–control studies published up to July 2012. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.

Ultimately, 17 studies, comprising 4123 lung cancer cases and 5597 controls were included. Overall, for T allele carriers (TC + TT) versus the wild-type homozygotes (CC), the pooled OR was 0.95 (95% CI = 0.87-1.04 P = 0.228 for heterogeneity), for TT versus CC the pooled OR was 0.99 (95% CI = 0.86-1.15 P = 0.315 for heterogeneity). In the stratified analysis by ethnicity, histological types of lung cancer and smoking status, no any significantly risks were found for (C/T + T/T) vs C/C or T/T vs C/C. No publication bias was found by using the funnel plot and Egger's test.

Overall, there is no evidence showing a significant correlation between XRCC3 Thr241Met polymorphism and lung cancer risk stratified analysis by ethnicity, histology and smoking status.

【 授权许可】

   
2013 Zhan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 2003, 123:21-49.
• [2]Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
• [3]Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AA, Eng P, Koong HN, Thirugnanam A, Tan EH: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006, 24:2245-2251.
• [4]Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005, 161:1-14.
• [5]Spitz MR, Wu X, Wang Y, Wang LE, Shete S, et al.: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001, 61:1354-1357.
• [6]Zhan P, Wang Q, Wei SZ, Wang J, Qian Q, Yu LK, Song Y: ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case–control studies. J Thorac Oncol 2010, 5(9):1337-1345.
• [7]Ji YN, Zhan P, Wang J, Qiu LX, Yu LK: APE1 Asp148Glu gene polymorphism and lung cancer risk: a meta-analysis. Mol Biol Rep 2011, 38(7):4537-4543.
• [8]Tebbs RS, Zhao Y, Tucker JD, et al.: Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci USA 1995, 92:6354-6358.
• [9]Lee JM, Lee YC, Yang SY, Yang PW, Luh SP, Lee CJ, Chen CJ, Wu MT: Genetic polymorphisms of XRCC1 and risk of the esophageal cancer. Int J Cancer 2001, 95:240-246.
• [10]Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Cementano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P: XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001, 22:1437-1445.
• [11]Cochran WG: The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
• [12]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
• [13]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [14]Tobias A: Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999, 8:15-17.
• [15]Egger M, Davey Smith G, Schneider M, Minder C: Bias in metaanalysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [16]David-Beabes GL, Lunn RM, London SJ: No association between the XPD(Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10:911-912.
• [17]Misra RR, Ratnasinghe D, Tangrea JA, et al.: Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE / ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 2003, 191:171-178.
• [18]Wang Y, Liang D, Spitz MR, et al.: XRCC3 genetic polymorphism, smoking, and lung carcinoma risk in minority populations. Cancer 2003, 98:1701-1706.
• [19]Popanda O, Schattenberg T, Phong CT, et al.: Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004, 25:2433-2441.
• [20]Jacobsen NR, Raaschou-Nielsen O, Nexo B, et al.: XRCC3 polymorphisms and risk of lung cancer. Cancer Lett 2004, 213:67-72.
• [21]Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW: Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen 2004, 44:74-82.
• [22]Matullo G, Dunning AM, Guarrera S, et al.: DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006, 27:997-1007.
• [23]Zienolddiny S, Campa D, Lind H, et al.: Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006, 27:560-567.
• [24]Ryk C, Kumar R, Thirumaran RK, Hou SM: Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Canc 2006, 54:285-292.
• [25]Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, et al.: Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer 2007, 7:162. BioMed Central Full Text
• [26]Zhang ZL, Zhou CC, Zhang J, Tang L, Su B: Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 2007, 30:936-940.
• [27]Improta G, Sgambato A, Bianchino G, et al.: Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case–control study in a Southern Italian population. Anticancer Res 2008, 28:2941-2946.
• [28]Xia W, Zhang Y, Su D, Shi F: Association of single nucleotide polymorphisms of DNA repair gene XRCC3-241 with non-small cell lung cancer. Zhejiang Med J 2008, 30:1291-1293.
• [29]Osawa K, Miyaishi A, Uchino K, Osawa Y, Inoue N, Nakarai C, Tsutou A, Kido Y, Yoshimura M, Tsubota N, Takahashi J: APEX1 Asp148Glu gene polymorphism is a risk factor for lung cancer in relation to smoking in Japanese. Asian Pac J Cancer Prev 2010, 11(5):1181-1186.
• [30]Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K: Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2011, 73(2):138-146. Epub 2010 Dec 30
• [31]Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y: Genetic polymorphisms involved in carcinogen metabolism and DNA repair and lung cancer risk in a Japanese population. J Thorac Oncol 2012, 7(6):954-962.
• [32]Hirschhorn JN, Lohmueller K, Byrne E: A comprehensive reviewof genetic association studies. Genet Med 2002, 4:45-61.
• [33]Sato S, Nakamura Y, Tsuchiya E: Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 1994, 54:5652-5655.
• [34]Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ, Heath CW: Family history and risk of fatal prostate cancer. Epidemiology 1997, 8:653-659.